ClinicalTrials.gg
RecruitingNCT07105787StepuPUpdated Aug 6, 2025

Steps Against the Burden of Parkinson's Disease - TelAviv/Bologna

An interventional study of SDTT + VR triggered adaptations and Speed-dependent treadmill training (SDTT) in Parkinson Disease and Falls, sponsored by University of Kiel. Recruiting at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by University of Kiel · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Parkinson Disease with a site in Israel — 17 open to participants now, 24 under way, 1 of them phase 3. Parkinson Disease · Israel.

Planned enrollment
49th of 84
42 · median 60
Started
2025
with 3 others
No phase
28 of 124
4 open now
Primary completion
2026-03
later than 7 of 23 live
Registered
119th of 124
by date

Among the 124 studies in Parkinson Disease with a site in Israel, this one is the 49th largest by planned enrollment of the 84 interventional ones that give a count, is one of 4 that started in 2025, is one of 28 with no phase, reaches primary completion later than 7 of the 23 other live ones, and was the 119th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

17 of the 124 studies in Parkinson Disease with a site in Israel are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Parkinson Disease with a site in Israel, or all of them as a file.
02

Study summary

Parkinson's disease (PD) affects over 10 million worldwide, causing unstable gait and falls in 70% of patients despite medication. This leads to confidence loss, isolation, fractures, and hospitalizations. Treadmill training, augmented by mechanical/virtual-reality triggers, has proven effective in enhancing gait and reducing falls. However, underlying treadmill training mechanisms are unclear. To personalize training, we'll explore how PD patients benefit and transfer effects to daily life.

This trial is part of three parallel randomized controlled trials within the Steps Against the Burden of Parkinson's Disease (CT-IDs: 6ef2e427b002, 6ef2e427b003, 6ef2e427b004) project, which will perform a pooled analysis across all sites in addition to individual RCT analyses. Each trial adheres to a shared core protocol while allowing for adaptations in the perturbation protocol, ensuring that data can be combined. Importantly, mechanistic findings and outcomes from this specific RCT will be reported independently, but also as part of a pooled analysis.

In this trials, PD patients will undergo treadmill training with and without adaptaions (perturbations). 12 sessions of treadmill training will be provided, with pre/post assessments and a follow-up with pre/post assessments and a follow-up at 8 to 12 weeks after the post assessment. For post treadmill training a phone app will be offered as a home-based speed dependent walk training intervention. This intervention is an App based training for gait adaptability and allows users to set their own training time and pace. It delivers a rhythmic metronomic beat for three different walking speeds, designed to trigger movement and encourage better walking patterns.. Gait improvements are expected, driven by sensorimotor integration improving balance control. Biomechanical data analysis will reveal enhanced foot placement control. Neurophysiological changes will be studied through EEG and EMG, aiming to find improved gait stability with reduced EEG beta power and increased EEG-EMG coherence.

Gait improvement in the lab might not correlate with daily-life results. Gait self-efficacy could influence transfer, prompting investigation into mechanistic associations with mobility outcomes. Remote digital tools will assess week-long mobility outcomes, employing machine learning to comprehend why some improve both in lab and life, while others don't. This will uncover mechanisms translating treatment effects into real-world outcomes, aiding personalized intervention development.

Read the detailed description

i. Rationale The rationale of this trial is that speed dependent treadmill training (SDTT) improves gait through improved sensorimotor integration, with changes in cortical activity as neural correlates. Additional benefits of treadmill training can be seen if perturbation or adaptations are added. This is based on the idea, that in addition to the sensorimotor integration the reactive balance in trained as well18. Furthermore, it hypothesizes that treadmill training and its effects on gait quality will improve gait self-efficacy, which mediates and/or modifies transfer of training effects to improved daily-life gait.

ii. Objectives

Thus, the objectives of our StepuP project are:

  1. To understand the kinematic and neural mechanisms that underlie improvements in gait due to treadmill training with and without mechanically and VR-triggered gait adaptations in people with PD;
  2. To assess to what extent improvements in gait due to treadmill training, as measured in the lab, transfer to improvements in daily life mobility;
  3. To understand the mechanisms that underpin transfer from improvements in gait to improvements of mobility in daily life in people with PD;
  4. To understand for whom treadmill training improves lab-based gait characteristics and for whom it does not, and understand for whom treadmill training improves mobility in daily life and for whom it does not.

Attaining these objectives will provide a better understanding of the successes and failures of treadmill training to improve gait stability and prevent falls in people with PD at an individual level, which in the medium term will allow targeted delivery of such interventions and in the long term will allow personalization of such interventions to improve outcomes for all.

iii. Endpoints Concerning the endpoints, this trial examines the effect of treadmill training with and without perturbations on gait performance, and neural correlates in people with PD. The primary endpoint is (change in) gait speed, secondary endpoints are divided into three groups (clinical, kinematic and neurophysiological). Clinical measures are used to assess the effect of training on disease symptoms. Kinematic measures are changes from baseline to follow-up, all under controlled conditions (treadmill), and provide insight into gait performance and quality. Neurophysiological measures aim to understand the neural control mechanisms underlying the training effects. On an exploratory level, the study aims to assess the training effects on daily-life gait by using wearable devices and assess gait self-efficacy using previously validated questionnaires.

03

Conditions studied

  • Parkinson Disease
  • Falls

Browse trials for

Keywords

  • EEG
  • EMG
  • perturbation
  • daily-life gait
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of PD according to the MDS Criteria
  2. Hoehn and Yahr stages I to III;
  3. Movement Disorder Society-sponsored version of the Unified Parkinson Disease Rating Scale (MDS-UPDRS) gait sub-score of 1 or more
  4. Signed to participation

Exclusion criteria

Exclusion criteria

  • Any known general health condition likely to interfere with or to pose a to non-medically supervised physical exercise.
  • Moderate or severe depression (BDI-II ≥18)
  • Cognitive impairment which may preclude the possibility to provide a fully to enrolment.
  • Linguistic comprehension capacity less than 75% in ordinary conversation
  • Severe psychiatric comorbidity which may interfere with compliance to the study protocol History of or current status of substance dependency
  • Unable to walk less than 1 floor
  • Thoracic pain in the last 4 weeks
  • Currently enrolled in other interventional studies
  • Implanted Deep Brain Stimulation device
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Experimental

    The experimental group will engage in 12-sessions of SDTT with additional virtual reality triggered adaptations, contrasting with the control group undergoing regular SDTT.

    Other: SDTT + VR triggered adaptations

  • Active comparator
    Control

    Other: Speed-dependent treadmill training (SDTT)

Interventions

  • OtherSDTT + VR triggered adaptations

    The SDTT+ VR triggered adaptations program will trigger reactive gait adaptations by presenting obstacles in VR.

  • OtherSpeed-dependent treadmill training (SDTT)

    This training methodology focuses on adjusting the treadmill's speed according to the individual's walking pace, creating a more dynamic and adaptive exercise environment. SDTT is designed to mimic real-world walking conditions and challenges, promoting neuromuscular coordination, balance, and overall mobility. By tailoring the treadmill speed to match the user's gait, SDTT encourages the development of natural and efficient walking patterns. This training technique has shown promise in various clinical settings, aiding individuals with gait impairments caused by neurological conditions, musculoskeletal disorders, or post-injury rehabilitation. Its adaptability allows for progressive adjustments as a person's walking abilities improve, making it a versatile tool for optimizing gait mechanics and functional mobility. To ensure continued progress and integration into daily life, home-based walking training, supported by a phone application, will be included between T1 and T2.

06

What researchers measure

Primary outcomes

  1. Gait speed - T0

    Comfortable walking speed overground

    Time frame: Baseline

  2. Gait speed - T1

    Comfortable walking speed overground

    Time frame: After Intervention (2-12 weeks)

  3. Gait speed - T2

    Comfortable walking speed overground

    Time frame: After Follow-up 12±2 weeks following T1 (20-32 weeks)

Secondary outcomes

  1. Fall events (occurrence and frequency) and fall related injuries - T0

    The number of falls and whether the falls were injurious will be recorded. Twelve-month retrospective.

    Time frame: Baseline (T0)

  2. Fracture history - T0

    Number and type of fracture sustained will be recorded. Twelve-month retrospective.

    Time frame: Baseline (T0)

  3. Medication - T0

    Current medication will be recorded at each visit.

    Time frame: Baseline (T0)

  4. Medication - T1

    Current medication will be recorded at each visit.

    Time frame: After Intervention (2-12 weeks)

  5. Medication - T2

    Current medication will be recorded at each visit.

    Time frame: Follow-up 12±2 weeks following T1

  6. Euro-Quality of life (EQ-5D) - T0

    The first part is a descriptive system, assessing health in five dimensions.The second part of the questionnaire consists of a visual analog scale (VAS) on which patients mark their perceived level of health on a scale ranging from 0 (worst conceivable state of health) to 100 (best conceivable state of health).

    Time frame: Baseline (T0)

  7. Euro-Quality of life (EQ-5D) - T1

    The first part is a descriptive system, assessing health in five dimensions.The second part of the questionnaire consists of a visual analog scale (VAS) on which patients mark their perceived level of health on a scale ranging from 0 (worst conceivable state of health) to 100 (best conceivable state of health).

    Time frame: After Intervention (2-12 weeks)

  8. Euro-Quality of life (EQ-5D) - T2

    The first part is a descriptive system, assessing health in five dimensions.The second part of the questionnaire consists of a visual analog scale (VAS) on which patients mark their perceived level of health on a scale ranging from 0 (worst conceivable state of health) to 100 (best conceivable state of health).

    Time frame: Follow-up 12±2 weeks following T1

  9. Frailty Index (FI) - T0

    Measures frailty based on five criteria: shrinking, low physical endurance/energy, low physical activity, weakness, and slow walking speed.

    Time frame: Baseline (T0)

  10. Frailty Index (FI) - T1

    Measures frailty based on five criteria: shrinking, low physical endurance/energy, low physical activity, weakness, and slow walking speed. For the Frailty Index, higher scores mean a worse outcome (increased frailty).

    Time frame: After Intervention (2-12 weeks)

  11. Frailty Index (FI) - T2

    Measures frailty based on five criteria: shrinking, low physical endurance/energy, low physical activity, weakness, and slow walking speed. For the Frailty Index, higher scores mean a worse outcome (increased frailty).

    Time frame: Follow-up 12±2 weeks following T1

  12. Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scale - T0

    Measures fatigue during usual daily activities over the past week. The FACIT-F scale consists of 13 items, each scored from 0 (Not at all) to 4 (Very much). Some items are reverse-scored. The total score ranges from 0 to 52. For the FACIT-F scale, higher scores indicate less fatigue (a better outcome).

    Time frame: Baseline (T0)

  13. Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scale - T1

    Measures fatigue during usual daily activities over the past week. The FACIT-F scale consists of 13 items, each scored from 0 (Not at all) to 4 (Very much). Some items are reverse-scored. The total score ranges from 0 to 52. For the FACIT-F scale, higher scores indicate less fatigue (a better outcome).

    Time frame: After Intervention (2-12 weeks)

  14. Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scale - T2

    Measures fatigue during usual daily activities over the past week. The FACIT-F scale consists of 13 items, each scored from 0 (Not at all) to 4 (Very much). Some items are reverse-scored. The total score ranges from 0 to 52. For the FACIT-F scale, higher scores indicate less fatigue (a better outcome).

    Time frame: Follow-up 12±2 weeks following T1

  15. Kinematics: 3D motion capture data - T0

    3D motion capture data.

    Time frame: Baseline

  16. Kinematics: 3D motion capture data - T1

    3D motion capture data.

    Time frame: After Intervention (2-12 weeks)

  17. Kinematics: 3D motion capture data - T2

    3D motion capture data.

    Time frame: Follow-up 12±2 weeks following T1

  18. Electroencephalography (EEG) - T0

    EEG measures brain activity to assess cortical involvement and sensorimotor integration for foot placement control. We'll specifically analyze beta power and beta band corticomuscular coherence with the rectus femoris muscle. Before analysis, EEG data will be cleaned using filtering and ICA to remove artifacts like muscle and eye movements. Coherence will be computed across the gait cycle using time-normalized EEG and EMG cross-spectra, and beamforming will localize sources.

    Time frame: Baseline

  19. Electroencephalography (EEG) - T1

    EEG measures brain activity to assess cortical involvement and sensorimotor integration for foot placement control. We'll specifically analyze beta power and beta band corticomuscular coherence with the rectus femoris muscle. Before analysis, EEG data will be cleaned using filtering and ICA to remove artifacts like muscle and eye movements. Coherence will be computed across the gait cycle using time-normalized EEG and EMG cross-spectra, and beamforming will localize sources.

    Time frame: After Intervention (2-12 weeks)

  20. Electroencephalography (EEG) - T2

    EEG measures brain activity to assess cortical involvement and sensorimotor integration for foot placement control. We'll specifically analyze beta power and beta band corticomuscular coherence with the rectus femoris muscle. Before analysis, EEG data will be cleaned using filtering and ICA to remove artifacts like muscle and eye movements. Coherence will be computed across the gait cycle using time-normalized EEG and EMG cross-spectra, and beamforming will localize sources.

    Time frame: Follow-up 12±2 weeks following T1

  21. Electromyography (EMG) - T0

    Surface EMG records electrical activity of superficial muscles to assess muscle function, fatigue, and activation patterns.

    Time frame: Baseline

  22. Electromyography (EMG) - T1

    Surface EMG records electrical activity of superficial muscles to assess muscle function, fatigue, and activation patterns.

    Time frame: After Intervention (2-12 weeks)

  23. Electromyography (EMG) - T2

    Surface EMG records electrical activity of superficial muscles to assess muscle function, fatigue, and activation patterns.

    Time frame: Follow-up 12±2 weeks following T1

  24. Gait speed (Preferred and maximal) - T0

    Preferred gait speed and maximal gait speed using a 20-m walk test will be derived.

    Time frame: Baseline

  25. Gait speed (Preferred and maximal) - T1

    Preferred gait speed and maximal gait speed using a 20-m walk test will be derived.

    Time frame: After Intervention (2-12 weeks)

  26. Gait speed (Preferred and maximal) - T2

    Preferred gait speed and maximal gait speed using a 20-m walk test will be derived.

    Time frame: Follow-up 12±2 weeks following T1

  27. Use of mobility aids - T0

    The use of commonly used walking aids (indoor and outdoor) will be recorded.

    Time frame: Baseline

  28. Use of mobility aids - T2

    The use of commonly used walking aids (indoor and outdoor) will be recorded.

    Time frame: Follow-up 12±2 weeks following T1

  29. Timed Up and Go (TUG) - T0

    A common clinical measure to assess mobility, balance, and walking ability in older adults.

    Time frame: Baseline

  30. Timed Up and Go (TUG) - T1

    A common clinical measure to assess mobility, balance, and walking ability in older adults.

    Time frame: After Intervention (2-12 weeks)

  31. Timed Up and Go (TUG) - T2

    A common clinical measure to assess mobility, balance, and walking ability in older adults.

    Time frame: Follow-up 12±2 weeks following T1

  32. Two-minute walking test (2MWT) - T0

    Measures functional exercise capacity. Distance in meters covered in 6 minutes is recorded.

    Time frame: Baseline

  33. Two-minute walking test (2MWT) - T1

    Measures functional exercise capacity. Distance in meters covered in 6 minutes is recorded.

    Time frame: After Intervention (2-12 weeks)

  34. Two-minute walking test (2MWT) - T2

    Measures functional exercise capacity. Distance in meters covered in 6 minutes is recorded.

    Time frame: Follow-up 12±2 weeks following T1

  35. Mini-BESTest - T0

    The Mini-BESTest (Mini-Balance Evaluation Systems Test) is a clinical balance assessment tool designed to evaluate various balance control systems. It assesses an individual's balance and stability on a series of functional tasks. The unabbreviated scale title is Mini-Balance Evaluation Systems Test (Mini-BESTest). It has a minimum value of 0 and a maximum value of 28. The Mini-BESTest is comprised of 14 items, each scored on a 3-point ordinal scale (0 = severe impairment, 1 = moderate impairment, 2 = no impairment). The scores from all items are summed to provide a total score. Higher scores on the Mini-BESTest indicate better balance and stability, representing a better outcome.

    Time frame: Baseline

  36. Mini-BESTest - T1

    The Mini-BESTest (Mini-Balance Evaluation Systems Test) is a clinical balance assessment tool designed to evaluate various balance control systems. It assesses an individual's balance and stability on a series of functional tasks. The unabbreviated scale title is Mini-Balance Evaluation Systems Test (Mini-BESTest). It has a minimum value of 0 and a maximum value of 28. The Mini-BESTest is comprised of 14 items, each scored on a 3-point ordinal scale (0 = severe impairment, 1 = moderate impairment, 2 = no impairment). The scores from all items are summed to provide a total score. Higher scores on the Mini-BESTest indicate better balance and stability, representing a better outcome.

    Time frame: After Intervention (2-12 weeks)

  37. Mini-BESTest - T2

    The Mini-BESTest (Mini-Balance Evaluation Systems Test) is a clinical balance assessment tool designed to evaluate various balance control systems. It assesses an individual's balance and stability on a series of functional tasks. The unabbreviated scale title is Mini-Balance Evaluation Systems Test (Mini-BESTest). It has a minimum value of 0 and a maximum value of 28. The Mini-BESTest is comprised of 14 items, each scored on a 3-point ordinal scale (0 = severe impairment, 1 = moderate impairment, 2 = no impairment). The scores from all items are summed to provide a total score. Higher scores on the Mini-BESTest indicate better balance and stability, representing a better outcome.

    Time frame: Follow-up 12±2 weeks following T1

  38. Modified Gait Efficacy Scale (mGES) - T0

    The Modified Gait Efficacy Scale (mGES) assesses an individual's confidence in their walking ability across various challenging everyday circumstances. It is a self-report measure. The unabbreviated scale title is Modified Gait Efficacy Scale (mGES). It has a minimum value of 0 and a maximum value of 100. The mGES typically consists of several items where individuals rate their confidence on a scale (e.g., 0-10 or 0-100) for various walking situations. The total score is often calculated as an average or sum and then converted to a percentage. Higher scores on the Modified Gait Efficacy Scale indicate greater walking confidence, representing a better outcome.

    Time frame: Baseline

  39. Modified Gait Efficacy Scale (mGES) - T1

    The Modified Gait Efficacy Scale (mGES) assesses an individual's confidence in their walking ability across various challenging everyday circumstances. It is a self-report measure. The unabbreviated scale title is Modified Gait Efficacy Scale (mGES). It has a minimum value of 0 and a maximum value of 100. The mGES typically consists of several items where individuals rate their confidence on a scale (e.g., 0-10 or 0-100) for various walking situations. The total score is often calculated as an average or sum and then converted to a percentage. Higher scores on the Modified Gait Efficacy Scale indicate greater walking confidence, representing a better outcome.

    Time frame: After Intervention (2-12 weeks)

  40. Modified Gait Efficacy Scale (mGES) - T2

    The Modified Gait Efficacy Scale (mGES) assesses an individual's confidence in their walking ability across various challenging everyday circumstances. It is a self-report measure. The unabbreviated scale title is Modified Gait Efficacy Scale (mGES). It has a minimum value of 0 and a maximum value of 100. The mGES typically consists of several items where individuals rate their confidence on a scale (e.g., 0-10 or 0-100) for various walking situations. The total score is often calculated as an average or sum and then converted to a percentage. Higher scores on the Modified Gait Efficacy Scale indicate greater walking confidence, representing a better outcome.

    Time frame: Follow-up 12±2 weeks following T1

  41. Hand grip strength - T0

    Hand grip strength.

    Time frame: Baseline

  42. Short Falls Efficacy Scale International (Short FES-i) - T0

    The Short Falls Efficacy Scale International (Short FES-I) measures the level of concern about falling during social and physical activities, both inside and outside the home. It is a widely used self-report questionnaire. It has a minimum value of 7 and a maximum value of 28. The Short FES-I consists of 7 items. Each item is rated on a 4-point scale, from 1 (not concerned at all) to 4 (completely concerned). The scores for all 7 items are summed. Higher scores on the Short FES-I indicate a greater concern about falling, representing a worse outcome.

    Time frame: Baseline

  43. Short Falls Efficacy Scale International (Short FES-i) - T1

    The Short Falls Efficacy Scale International (Short FES-I) measures the level of concern about falling during social and physical activities, both inside and outside the home. It is a widely used self-report questionnaire. It has a minimum value of 7 and a maximum value of 28. The Short FES-I consists of 7 items. Each item is rated on a 4-point scale, from 1 (not concerned at all) to 4 (completely concerned). The scores for all 7 items are summed. Higher scores on the Short FES-I indicate a greater concern about falling, representing a worse outcome.

    Time frame: After Intervention (2-12 weeks)

  44. Short Falls Efficacy Scale International (Short FES-i) - T2

    The Short Falls Efficacy Scale International (Short FES-I) measures the level of concern about falling during social and physical activities, both inside and outside the home. It is a widely used self-report questionnaire. It has a minimum value of 7 and a maximum value of 28. The Short FES-I consists of 7 items. Each item is rated on a 4-point scale, from 1 (not concerned at all) to 4 (completely concerned). The scores for all 7 items are summed. Higher scores on the Short FES-I indicate a greater concern about falling, representing a worse outcome.

    Time frame: Follow-up 12±2 weeks following T1

  45. Montreal Cognitive Assessment (MoCA) - T0

    The Montreal Cognitive Assessment (MoCA) is a quick screening tool designed to detect mild cognitive impairment, assessing a broad range of cognitive domains. It has a minimum value of 0 and a maximum value of 30. The MoCA assesses attention and concentration, executive functions, memory, language, visuospatial skills, conceptual thinking, calculations, and orientation. Each correct response contributes to the total score. A score of 26 or above is generally considered normal. Higher scores on the MoCA indicate better cognitive function, representing a better outcome.

    Time frame: Baseline

  46. Montreal Cognitive Assessment (MoCA) - T2

    The Montreal Cognitive Assessment (MoCA) is a quick screening tool designed to detect mild cognitive impairment, assessing a broad range of cognitive domains. It has a minimum value of 0 and a maximum value of 30. The MoCA assesses attention and concentration, executive functions, memory, language, visuospatial skills, conceptual thinking, calculations, and orientation. Each correct response contributes to the total score. A score of 26 or above is generally considered normal. Higher scores on the MoCA indicate better cognitive function, representing a better outcome.

    Time frame: Follow-up 12±2 weeks following T1

  47. Color Trail Test (CTT) - T0

    The Color Trail Test (CTT) is a neuropsychological assessment with two parts (CTT-1, CTT-2) that evaluates cognitive flexibility, visual scanning, and executive function. Participants connect numbered circles, then alternate between numbers and letters. Key measures are completion time (min 0s, max typically 120-240s) and errors. Lower times and fewer errors indicate better attention, mental flexibility, and processing speed, signifying a better outcome.

    Time frame: Baseline

  48. Color Trail Test (CTT) - T2

    The Color Trail Test (CTT) is a neuropsychological assessment with two parts (CTT-1, CTT-2) that evaluates cognitive flexibility, visual scanning, and executive function. Participants connect numbered circles, then alternate between numbers and letters. Key measures are completion time (min 0s, max typically 120-240s) and errors. Lower times and fewer errors indicate better attention, mental flexibility, and processing speed, signifying a better outcome.

    Time frame: Follow-up 12±2 weeks following T1

  49. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - T0

    The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a comprehensive, clinician-rated scale used to assess the severity and progression of Parkinson's Disease. Part III specifically focuses on the Motor Examination. It has a minimum value of 0 and a maximum value of 132 (sum of all 33 items in Part III, each scored 0-4). Part III consists of 33 items (e.g., speech, facial expression, rigidity, tremor, bradykinesia, gait, postural stability), each scored from 0 (normal) to 4 (severe impairment). The scores for all items are summed. Higher scores on the MDS-UPDRS Part III indicate greater motor impairment and more severe Parkinson's disease symptoms, representing a worse outcome.

    Time frame: Baseline

  50. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - T1

    The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a comprehensive, clinician-rated scale used to assess the severity and progression of Parkinson's Disease. Part III specifically focuses on the Motor Examination. It has a minimum value of 0 and a maximum value of 132 (sum of all 33 items in Part III, each scored 0-4). Part III consists of 33 items (e.g., speech, facial expression, rigidity, tremor, bradykinesia, gait, postural stability), each scored from 0 (normal) to 4 (severe impairment). The scores for all items are summed. Higher scores on the MDS-UPDRS Part III indicate greater motor impairment and more severe Parkinson's disease symptoms, representing a worse outcome.

    Time frame: After Intervention (2-12 weeks)

  51. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - T2

    The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a comprehensive, clinician-rated scale used to assess the severity and progression of Parkinson's Disease. Part III specifically focuses on the Motor Examination. It has a minimum value of 0 and a maximum value of 132 (sum of all 33 items in Part III, each scored 0-4). Part III consists of 33 items (e.g., speech, facial expression, rigidity, tremor, bradykinesia, gait, postural stability), each scored from 0 (normal) to 4 (severe impairment). The scores for all items are summed. Higher scores on the MDS-UPDRS Part III indicate greater motor impairment and more severe Parkinson's disease symptoms, representing a worse outcome.

    Time frame: Follow-up 12±2 weeks following T1

  52. New Freezing of Gait Questionnaire (NFOGQ) - T0

    The New Freezing of Gait Questionnaire (NFOGQ) is a patient-reported outcome measure specifically designed to detect and evaluate the impact and severity of freezing of gait (FOG) in individuals with Parkinson's disease or other neurological conditions. It has a minimum value of 0 and a maximum value of 45. The NFOGQ consists of 9 items, with a total score calculated by summing the scores for all items. Each item is typically scored on a 5-point Likert scale. Higher scores on the NFOGQ indicate a greater severity, frequency, and impact of freezing of gait, representing a worse outcome.

    Time frame: Baseline

  53. New Freezing of Gait Questionnaire (NFOGQ) - T1

    The New Freezing of Gait Questionnaire (NFOGQ) is a patient-reported outcome measure specifically designed to detect and evaluate the impact and severity of freezing of gait (FOG) in individuals with Parkinson's disease or other neurological conditions. It has a minimum value of 0 and a maximum value of 45. The NFOGQ consists of 9 items, with a total score calculated by summing the scores for all items. Each item is typically scored on a 5-point Likert scale. Higher scores on the NFOGQ indicate a greater severity, frequency, and impact of freezing of gait, representing a worse outcome.

    Time frame: After Intervention (2-12 weeks)

  54. New Freezing of Gait Questionnaire (NFOGQ) - T2

    The New Freezing of Gait Questionnaire (NFOGQ) is a patient-reported outcome measure specifically designed to detect and evaluate the impact and severity of freezing of gait (FOG) in individuals with Parkinson's disease or other neurological conditions. It has a minimum value of 0 and a maximum value of 45. The NFOGQ consists of 9 items, with a total score calculated by summing the scores for all items. Each item is typically scored on a 5-point Likert scale. Higher scores on the NFOGQ indicate a greater severity, frequency, and impact of freezing of gait, representing a worse outcome.

    Time frame: Follow-up 12±2 weeks following T1

  55. Home assessment: Steps per day - T0

    The steps per day will be recorded.

    Time frame: Baseline (T0)

  56. Home assessment: Steps per day - T1

    The steps per day will be recorded.

    Time frame: After Intervention (2-12 weeks)

  57. Home assessment: Steps per day - T2

    The steps per day will be recorded.

    Time frame: Follow-up 12±2 weeks following T1

  58. Home assessment: Amount and length of uninterrupted walk durations - T0

    The amount and length of uninterrupted walk durations will be determined.

    Time frame: Baseline (T0)

  59. Home assessment: Amount and length of uninterrupted walk durations - T1

    The amount and length of uninterrupted walk durations will be determined.

    Time frame: After Intervention (2-12 weeks)

  60. Home assessment: Amount and length of uninterrupted walk durations - T2

    The amount and length of uninterrupted walk durations will be determined.

    Time frame: Follow-up 12±2 weeks following T1

  61. Home assessment: Stride time variability - T0

    The stride time variability will be derived.

    Time frame: Baseline (T0)

  62. Home assessment: Stride time variability - T1

    The stride time variability will be derived.

    Time frame: After Intervention (2-12 weeks)

  63. Home assessment: Stride time variability - T2

    The stride time variability will be derived.

    Time frame: Follow-up 12±2 weeks following T1

  64. Home assessment: Symmetry of gait - T0

    Symmetry of gait will be determined.

    Time frame: Baseline (T0)

  65. Home assessment: Symmetry of gait - T1

    Symmetry of gait will be determined.

    Time frame: After Intervention (2-12 weeks)

  66. Home assessment: Symmetry of gait - T2

    Symmetry of gait will be determined.

    Time frame: Follow-up 12±2 weeks following T1

  67. Home assessment: FOG episodes, Medication, and Physical activity (self-reports) - T0

    FOG episodes, Medication and Physical activity will be recorded by self-reports.

    Time frame: Baseline (T0)

  68. Home assessment: FOG episodes, Medication, and Physical activity (self-reports) - T1

    FOG episodes, Medication and Physical activity will be recorded by self-reports.

    Time frame: After Intervention (2-12 weeks)

  69. Home assessment: Weekly Calendars for Physical activity, Falls and Injurious Falls - T0

    Weekly Calendars will be used to assess Physical activity, Falls and Injurious Falls.

    Time frame: Baseline (T0)

  70. Home assessment: Weekly Calendars for Physical activity, Falls and Injurious Falls - T1

    Weekly Calendars will be used to assess Physical activity, Falls and Injurious Falls.

    Time frame: After Intervention (2-12 weeks)

  71. Home assessment: Weekly Calendars for Physical activity, Falls and Injurious Falls - T2

    Weekly Calendars will be used to assess Physical activity, Falls and Injurious Falls.

    Time frame: Follow-up 12±2 weeks following T1

  72. Acceptability and satisfaction with the intervention (System Usability Scale and PACES) - T1

    The Physical Activity Enjoyment Scale (PACES) is a self-report questionnaire designed to measure an individual's enjoyment of physical activity. It typically consists of 18 items where participants rate their feelings about physical activity on a 7-point bipolar scale. It has a minimum possible score of 18 (if each item is rated '1') and a maximum possible score of 126 (if each item is rated '7'). Scores from all 18 items are summed to create a total score. Higher scores on the PACES indicate greater enjoyment of physical activity, representing a better outcome. Additionally it includes questions developed specifically for the components of this study.

    Time frame: After Intervention (2-12 weeks)

  73. Acceptability and satisfaction with the intervention (System Usability Scale and PACES) - T2

    The Physical Activity Enjoyment Scale (PACES) is a self-report questionnaire designed to measure an individual's enjoyment of physical activity. It typically consists of 18 items where participants rate their feelings about physical activity on a 7-point bipolar scale. It has a minimum possible score of 18 (if each item is rated '1') and a maximum possible score of 126 (if each item is rated '7'). Scores from all 18 items are summed to create a total score. Higher scores on the PACES indicate greater enjoyment of physical activity, representing a better outcome. Additionally it includes questions developed specifically for the components of this study.

    Time frame: Follow-up 12±2 weeks following T1

  74. Changes in attitudes towards physical activity (Exercise Self-Efficacy Scale) - T1

    The Exercise Self-Efficacy Scale (ESES) is designed to assess an individual's confidence in their ability to engage in regular exercise, particularly in challenging situations. There are various versions of self-efficacy scales, but they generally follow a similar structure. It has a minimum possible score of 0 (or the lowest point on the chosen confidence scale) and a maximum possible score of 100 (or the highest point on the chosen confidence scale). Participants typically rate their confidence for various exercise-related scenarios on a percentage scale, for instance, 0% = not at all confident to 100% = completely confident. The scores are then averaged or summed. Higher scores on the Exercise Self-Efficacy Scale indicate greater confidence in one's ability to exercise, representing a better outcome.

    Time frame: After Intervention (2-12 weeks)

  75. Changes in attitudes towards physical activity (Exercise Self-Efficacy Scale) - T2

    The Exercise Self-Efficacy Scale (ESES) is designed to assess an individual's confidence in their ability to engage in regular exercise, particularly in challenging situations. There are various versions of self-efficacy scales, but they generally follow a similar structure. It has a minimum possible score of 0 (or the lowest point on the chosen confidence scale) and a maximum possible score of 100 (or the highest point on the chosen confidence scale). Participants typically rate their confidence for various exercise-related scenarios on a percentage scale, for instance, 0% = not at all confident to 100% = completely confident. The scores are then averaged or summed. Higher scores on the Exercise Self-Efficacy Scale indicate greater confidence in one's ability to exercise, representing a better outcome.

    Time frame: Follow-up 12±2 weeks following T1

  76. Exit interviews (Barriers and enablers to long-term use) - T1

    Exit interviews will be conducted to explore the barriers and enablers to long-term use and reasons for ceased involvement (if applicable) using pre-prepared, open-ended questions according to qualitative interview methods.

    Time frame: After Intervention (2-12 weeks)

  77. Exit interviews (Barriers and enablers to long-term use) - T2

    Exit interviews will be conducted to explore the barriers and enablers to long-term use and reasons for ceased involvement (if applicable) using pre-prepared, open-ended questions according to qualitative interview methods.

    Time frame: Follow-up 12±2 weeks following T1

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2026, 12 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Aug 6, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Apr 30, 2026
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07105787
Lead sponsor
University of Kiel
Collaborators
IRCCS Istituto delle Scienze Neurologiche di Bologna, Tel-Aviv Sourasky Medical Center
Responsible party
Walter Maetzler (Prof. Dr., University of Kiel) — Principal investigator
First posted
Aug 6, 2025
Start date
Mar 31, 2025
Primary completion
Mar 31, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Aug 6, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion